Published in Women's Health Weekly, November 26th, 2009
"We explored this notion in a similar experimental paradigm by administering a P-receptor antagonist (mifepristone) after P withdrawal while continuing E-2. Studies were performed in seven ovulatory, non-obese women. Transdermal E-2 (0.2 mg/day) and oral micronized P (100 mg every 8 h) were started within 24 h of the LH surge and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly